PE20050726A1 - Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos - Google Patents

Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos

Info

Publication number
PE20050726A1
PE20050726A1 PE2004000739A PE2004000739A PE20050726A1 PE 20050726 A1 PE20050726 A1 PE 20050726A1 PE 2004000739 A PE2004000739 A PE 2004000739A PE 2004000739 A PE2004000739 A PE 2004000739A PE 20050726 A1 PE20050726 A1 PE 20050726A1
Authority
PE
Peru
Prior art keywords
derivatives
indol
nitro
alkyl
independently
Prior art date
Application number
PE2004000739A
Other languages
English (en)
Inventor
Zueras Alberto Dorzal
Vidal Ramon Merce
Soler Xavier Codony
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of PE20050726A1 publication Critical patent/PE20050726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1-SULFONILINDOLES, DE FORMULA (I), EN DONDE R1 ES -NR7R8 O UN CICLOALIFATICO DE 5 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDOS, SATURADOS EL CUAL PUEDE CONDENSARSE CON UN SISTEMA ANULAR ALIFATICO; R2, R3, R4, R5 Y R6 SON INDEPENDIENTEMENTE H, F, Cl, Br, CIANO, NITRO, -NR9R10, HN2, ALQUILO(C1-C2), ENTRE OTROS; R7 Y R8 SON H O UN ALIFATICO(C1-C4) O JUNTOS CON EL ATOMO PUENTE DE N FORMAN UN ANILLO HETEROCICLICO DE 5 A 6 MIEMBROS; A Y B SON INDEPENDIENTEMENTE, ALQUILO(C1-C6), ALQUENILO O ALQUINILO(C2-C6) O JUNTOS CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN ANILLO CICLOALQUILICO(C3-C6), OPCIONALMENTE SATURADOS PERO NO AROMATICOS, COMO CICLOHEXIL; n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: 1-CICLOHEXANOSULFONIL-3-(1-METIL-1,2,3,6-TETRAHIDROPIRIDIN-4-IL)-5-NITRO-1H-INDOL, CLORHIDRATO DE 1-CICLOHEXANOSULFONIL-5-FLUORO-3-(1,2,3,5,8-8a-HEXAHIDRO-INDOLIZIN-7-IL)-1H-INDOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE OBTENCION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS MUESTRAN AFINIDAD POR EL RECEPTOR 5TH6, POR LO QUE SON UTILES EN LA PREVENCION Y TRATAMIENTO DE DESORDENES RELACIONADOS CON LA INGESTION DE ALIMENTOS, REGULACION DEL APETITO, TRANSTORNOS GASTROINTESTINALES Y DEL SISTEMA NERVIOSO CENTRAL
PE2004000739A 2003-07-30 2004-08-02 Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos PE20050726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200301806A ES2222828B1 (es) 2003-07-30 2003-07-30 Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.

Publications (1)

Publication Number Publication Date
PE20050726A1 true PE20050726A1 (es) 2005-11-16

Family

ID=34130540

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000739A PE20050726A1 (es) 2003-07-30 2004-08-02 Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos

Country Status (21)

Country Link
US (1) US7655690B2 (es)
EP (1) EP1648443B1 (es)
JP (1) JP2007500168A (es)
KR (1) KR20060056347A (es)
CN (1) CN1863527A (es)
AR (1) AR045159A1 (es)
AT (1) ATE473738T1 (es)
AU (1) AU2004262490A1 (es)
BR (1) BRPI0413062A (es)
CA (1) CA2533996A1 (es)
DE (1) DE602004028125D1 (es)
EC (1) ECSP066330A (es)
ES (2) ES2222828B1 (es)
IL (1) IL172956A0 (es)
MX (1) MXPA06001229A (es)
NO (1) NO20060342L (es)
PE (1) PE20050726A1 (es)
RU (1) RU2006105782A (es)
TW (1) TW200509908A (es)
WO (1) WO2005013974A1 (es)
ZA (1) ZA200600427B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246721B1 (es) * 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
CA2637531A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
AR060451A1 (es) 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
WO2007138611A1 (en) * 2006-05-30 2007-12-06 Suven Life Sciences Limited 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands
RU2449990C2 (ru) * 2006-07-03 2012-05-10 Биовитрум Аб (Пабл) Индолы в качестве модуляторов 5-ht6
ES2357584T3 (es) * 2007-01-08 2011-04-27 Suven Life Sciences Limited Compuestos de 5-(heterociclil) alquil-n-(arilsulfonil)indol y su uso como ligandos de 5-th6.
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
WO2008136017A1 (en) 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
ATE499099T1 (de) * 2007-07-19 2011-03-15 Esteve Labor Dr Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
EP2020230B1 (en) 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
JP5536781B2 (ja) 2008-09-17 2014-07-02 スヴェン・ライフ・サイエンシズ・リミテッド アリールスルホンアミドアミン化合物および５−ｈｔ６リガンドとしてのそれらの使用
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
CN104276993B (zh) * 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CN104529866A (zh) * 2014-12-12 2015-04-22 广东东阳光药业有限公司 吲哚类衍生物及其在药物上的应用
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
JP4969004B2 (ja) * 1999-08-12 2012-07-04 エヌピーエス ファーマシューティカルズ，インク． セロトニン受容体親和性を有するアザインドール
EP1355900B1 (en) * 2000-12-22 2006-05-24 Wyeth Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
CA2432654A1 (en) * 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
BR0206595A (pt) * 2001-01-30 2004-07-13 Lilly Co Eli Composto, composição farmacêutica, e uso de um composto
JP2005506368A (ja) * 2001-10-23 2005-03-03 ビオヴィトルム・アクチボラゲット 肥満の処置におけるまたは食物摂取の減少のためのインドールおよびインドリン誘導体の使用
TW200301251A (en) * 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
ES2222828B1 (es) 2006-04-16
TW200509908A (en) 2005-03-16
EP1648443B1 (en) 2010-07-14
IL172956A0 (en) 2006-06-11
ATE473738T1 (de) 2010-07-15
BRPI0413062A (pt) 2006-10-17
JP2007500168A (ja) 2007-01-11
MXPA06001229A (es) 2006-05-15
CA2533996A1 (en) 2005-02-17
AR045159A1 (es) 2005-10-19
KR20060056347A (ko) 2006-05-24
AU2004262490A1 (en) 2005-02-17
US20070060581A1 (en) 2007-03-15
US7655690B2 (en) 2010-02-02
WO2005013974A1 (en) 2005-02-17
RU2006105782A (ru) 2007-09-20
ES2222828A1 (es) 2005-02-01
ECSP066330A (es) 2006-08-30
NO20060342L (no) 2006-01-23
ES2348621T3 (es) 2010-12-09
CN1863527A (zh) 2006-11-15
DE602004028125D1 (de) 2010-08-26
ZA200600427B (en) 2007-03-28
EP1648443A1 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
PE20050726A1 (es) Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos
AR037222A1 (es) Un derivado de indol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y un procedimiento para preparar dicha composicion
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
TW200612936A (en) Indole derivatives
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
UY28150A1 (es) Agentes terapeuticos
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
AR030913A1 (es) Un compuesto derivado de indolina, su uso, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y un procedimiento para preparar dicha composicion
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
PE20091116A1 (es) Derivados de piridina y pirazina como inhibidores de tirosina quinasas
PE20040840A1 (es) Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih
ECSP067079A (es) Derivados de ácido carboxílico de bencimidazolona
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
PE20080010A1 (es) Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
AR050274A1 (es) Derivados triciclicos del indeno-pirrol como moduladores de la serotonina
GB0507601D0 (en) Compounds
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FX Voluntary withdrawal